IL136603A0 - N-benzyl-3-indenylacetamide derivatives for treating neoplasia - Google Patents
N-benzyl-3-indenylacetamide derivatives for treating neoplasiaInfo
- Publication number
- IL136603A0 IL136603A0 IL13660398A IL13660398A IL136603A0 IL 136603 A0 IL136603 A0 IL 136603A0 IL 13660398 A IL13660398 A IL 13660398A IL 13660398 A IL13660398 A IL 13660398A IL 136603 A0 IL136603 A0 IL 136603A0
- Authority
- IL
- Israel
- Prior art keywords
- benzyl
- indenylacetamide
- derivatives
- treating neoplasia
- arresting
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- NNPSGLWEKFBPKR-UHFFFAOYSA-N n-benzyl-2-(3h-inden-1-yl)acetamide Chemical class C=1CC2=CC=CC=C2C=1CC(=O)NCC1=CC=CC=C1 NNPSGLWEKFBPKR-UHFFFAOYSA-N 0.000 title abstract 2
- 230000009826 neoplastic cell growth Effects 0.000 title abstract 2
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 239000007859 condensation product Substances 0.000 abstract 1
- -1 heterocyclic aldehydes Chemical class 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 210000005170 neoplastic cell Anatomy 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Quinoline Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyridine Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/989,353 US5948779A (en) | 1997-12-12 | 1997-12-12 | Substituted condensation products of n-benzyl-3-indenyl acetamides with heterocyclic aldehydes |
| US09/206,245 US6066634A (en) | 1997-12-12 | 1998-12-07 | Substituted condensation products of N-benzyl-3-indenylacetamides heterocyclic aldehydes for neoplasia |
| PCT/GB1998/003712 WO1999031065A1 (en) | 1997-12-12 | 1998-12-11 | N-benzyl-3-indenylacetamides derivatives for treating neoplasia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL136603A0 true IL136603A0 (en) | 2001-06-14 |
Family
ID=26901185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13660398A IL136603A0 (en) | 1997-12-12 | 1998-12-11 | N-benzyl-3-indenylacetamide derivatives for treating neoplasia |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US6166053A (https=) |
| EP (1) | EP1044187B1 (https=) |
| JP (1) | JP4307719B2 (https=) |
| CN (1) | CN100436418C (https=) |
| AT (1) | ATE257152T1 (https=) |
| AU (1) | AU752072B2 (https=) |
| BR (1) | BR9813540A (https=) |
| CA (1) | CA2314339C (https=) |
| CZ (1) | CZ298826B6 (https=) |
| DE (1) | DE69820908T2 (https=) |
| ES (1) | ES2212383T3 (https=) |
| HU (1) | HU227153B1 (https=) |
| IL (1) | IL136603A0 (https=) |
| NO (1) | NO317097B1 (https=) |
| NZ (1) | NZ504958A (https=) |
| PL (1) | PL196936B1 (https=) |
| TR (1) | TR200001687T2 (https=) |
| WO (1) | WO1999031065A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE257152T1 (de) * | 1997-12-12 | 2004-01-15 | Osi Pharm Inc | N-benzyl-3-indenylaceamidderivative zur behandlung von neoplasia |
| IL132366A0 (en) * | 1998-10-15 | 2001-03-19 | Cell Pathways Inc | Methods for identifying compounds for inhibition of neoplastic lesions and pharmaceutical compositions containing such compounds |
| JP2004500425A (ja) * | 2000-04-19 | 2004-01-08 | リリー アイコス リミテッド ライアビリティ カンパニー | パーキンソン病の処置に対する環状ｇｍｐ特異的ホスホジエステラーゼインヒビターの使用 |
| DE10058663A1 (de) * | 2000-11-25 | 2002-05-29 | Merck Patent Gmbh | Verwendung von Thienopyrimidinen |
| WO2002067936A1 (en) * | 2001-02-21 | 2002-09-06 | Cell Pathways, Inc. | Methods for treatment of inflammatory bowel disease |
| DE10135815A1 (de) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
| US20030073740A1 (en) * | 2001-08-23 | 2003-04-17 | Whitehead Clark M. | Methods for treatment of lupus erythematosus |
| US20030073711A1 (en) * | 2001-08-23 | 2003-04-17 | Whitehead Clark M. | Methods for treatment of scleroderma |
| US6479493B1 (en) * | 2001-08-23 | 2002-11-12 | Cell Pathways, Inc. | Methods for treatment of type I diabetes |
| CN100398522C (zh) * | 2003-08-20 | 2008-07-02 | Irm责任有限公司 | 组织蛋白酶s的抑制剂 |
| US6995622B2 (en) * | 2004-01-09 | 2006-02-07 | Robert Bosh Gmbh | Frequency and/or phase compensated microelectromechanical oscillator |
| JP2008501407A (ja) | 2004-06-02 | 2008-01-24 | メリット ダイアモンド コーポレイション | 装身具のための快適な内側およびその内側を備える装身具 |
| CN1332930C (zh) * | 2005-08-05 | 2007-08-22 | 中国科学院上海有机化学研究所 | 制备乙氰菊酯前体的方法 |
| US8044048B2 (en) * | 2006-01-04 | 2011-10-25 | Southern Research Institute | Derivatives of sulindac, use thereof and preparation thereof |
| WO2009022756A1 (ja) * | 2007-08-13 | 2009-02-19 | Katayama Chemical Industries Co., Ltd. | 虚血性疾患の診断及び治療 |
| WO2010053910A1 (en) * | 2008-11-04 | 2010-05-14 | Wellstat Therapeutics Corporation | Synthesis of (phenylalkyloxy)phenyl-oxobutanoic acids |
| JP2013501665A (ja) | 2009-08-07 | 2013-01-17 | オークランド ユニサービシズ リミテッド | 道路から電気エネルギーを得る電気車両システム |
| US9862698B2 (en) | 2014-12-16 | 2018-01-09 | Adt Pharmaceuticals, Inc. | Indenyl compounds, pharmaceutical compositions, and medical uses thereof |
| US20160168108A1 (en) | 2014-12-16 | 2016-06-16 | Adt Pharmaceuticals, Inc. | Method of treating or preventing ras-mediated diseases |
| JP7169008B2 (ja) | 2018-04-26 | 2022-11-10 | エーディーティー ファーマシューティカルズ，エルエルシー | 抗がんインデン、インダン、アザインデン、アザインダン、医薬組成物および使用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU650720B2 (en) * | 1991-03-08 | 1994-06-30 | Fgn, Inc. | Method for treating patients with precancerous lesions by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof |
| US6063818A (en) * | 1996-06-13 | 2000-05-16 | Cell Pathways Inc. | Substituted benzylidene indenyl formamides, acetamides and propionamides |
| ATE257152T1 (de) * | 1997-12-12 | 2004-01-15 | Osi Pharm Inc | N-benzyl-3-indenylaceamidderivative zur behandlung von neoplasia |
| US5948779A (en) * | 1997-12-12 | 1999-09-07 | Cell Pathways, Inc. | Substituted condensation products of n-benzyl-3-indenyl acetamides with heterocyclic aldehydes |
-
1998
- 1998-12-11 AT AT98959050T patent/ATE257152T1/de not_active IP Right Cessation
- 1998-12-11 JP JP2000538992A patent/JP4307719B2/ja not_active Expired - Fee Related
- 1998-12-11 DE DE69820908T patent/DE69820908T2/de not_active Expired - Lifetime
- 1998-12-11 CA CA002314339A patent/CA2314339C/en not_active Expired - Fee Related
- 1998-12-11 CN CNB988118955A patent/CN100436418C/zh not_active Expired - Fee Related
- 1998-12-11 WO PCT/GB1998/003712 patent/WO1999031065A1/en not_active Ceased
- 1998-12-11 NZ NZ504958A patent/NZ504958A/xx unknown
- 1998-12-11 EP EP98959050A patent/EP1044187B1/en not_active Expired - Lifetime
- 1998-12-11 HU HU0100170A patent/HU227153B1/hu not_active IP Right Cessation
- 1998-12-11 IL IL13660398A patent/IL136603A0/xx active IP Right Grant
- 1998-12-11 TR TR2000/01687T patent/TR200001687T2/xx unknown
- 1998-12-11 BR BR9813540-6A patent/BR9813540A/pt not_active Application Discontinuation
- 1998-12-11 CZ CZ20002157A patent/CZ298826B6/cs not_active IP Right Cessation
- 1998-12-11 PL PL341151A patent/PL196936B1/pl not_active IP Right Cessation
- 1998-12-11 ES ES98959050T patent/ES2212383T3/es not_active Expired - Lifetime
- 1998-12-11 AU AU14981/99A patent/AU752072B2/en not_active Ceased
-
2000
- 2000-01-24 US US09/490,269 patent/US6166053A/en not_active Expired - Lifetime
- 2000-06-09 NO NO20002972A patent/NO317097B1/no not_active IP Right Cessation
- 2000-12-20 US US09/741,970 patent/US6426349B1/en not_active Expired - Fee Related
-
2002
- 2002-07-26 US US10/206,687 patent/US6610854B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US6610854B2 (en) | 2003-08-26 |
| CZ298826B6 (cs) | 2008-02-20 |
| US20030009033A1 (en) | 2003-01-09 |
| US6166053A (en) | 2000-12-26 |
| EP1044187B1 (en) | 2004-01-02 |
| NO20002972L (no) | 2000-08-09 |
| AU752072B2 (en) | 2002-09-05 |
| PL196936B1 (pl) | 2008-02-29 |
| JP4307719B2 (ja) | 2009-08-05 |
| EP1044187A1 (en) | 2000-10-18 |
| WO1999031065A1 (en) | 1999-06-24 |
| NO317097B1 (no) | 2004-08-09 |
| PL341151A1 (en) | 2001-03-26 |
| NO20002972D0 (no) | 2000-06-09 |
| US6426349B1 (en) | 2002-07-30 |
| NZ504958A (en) | 2003-03-28 |
| CZ20002157A3 (cs) | 2000-10-11 |
| HUP0100170A3 (en) | 2001-12-28 |
| CN100436418C (zh) | 2008-11-26 |
| HUP0100170A1 (hu) | 2001-07-30 |
| DE69820908D1 (de) | 2004-02-05 |
| CA2314339A1 (en) | 1999-06-24 |
| CN1281436A (zh) | 2001-01-24 |
| AU1498199A (en) | 1999-07-05 |
| BR9813540A (pt) | 2000-10-10 |
| ATE257152T1 (de) | 2004-01-15 |
| DE69820908T2 (de) | 2004-12-23 |
| JP2002508358A (ja) | 2002-03-19 |
| HU227153B1 (en) | 2010-08-30 |
| CA2314339C (en) | 2009-09-08 |
| TR200001687T2 (tr) | 2000-10-23 |
| ES2212383T3 (es) | 2004-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL136603A0 (en) | N-benzyl-3-indenylacetamide derivatives for treating neoplasia | |
| SG144712A1 (en) | Nordihydroguaiartic derivaties for use in treatment of tumors | |
| IL222002B (en) | A preparation of taxane for the treatment of cancer, restenosis and retinopathy | |
| MX9101913A (es) | Derivados de quinazolinas para potenciar la actividad antitumoral | |
| ZA200108258B (en) | Methods of inducing cancer cell death and tumor regression. | |
| HU9302384D0 (en) | 2,4-diamino-quinazoline derivatives and medical preparatives containing them | |
| NZ333399A (en) | Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis | |
| MY138883A (en) | Use of asiatic acid for treatment of cencer | |
| AU9312198A (en) | Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer | |
| WO2000055629A3 (en) | Methods of diagnosing and treating breast cancer | |
| ES2167401T3 (es) | Uso de ascorbil-gamma-linolenato o un ascorbil-dihomo-gamma-linolenato para el tratamiento de asma, cancer, enfermedades cardiovasculares y anti-inflamatorias. | |
| ZA982136B (en) | Novel carboxylic acid derivatives, their preparation and use in treating cancer. | |
| CA2298820A1 (en) | The use of 1,3,4,6-tetrahydroxy-helianthrone and its derivatives in photodynamic therapy and certain such novel derivatives | |
| PL357179A1 (en) | Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers | |
| ATE353016T1 (de) | Chelatiertes 8-hydroxychinolin zur behandlung von epithelialen verletzungen | |
| AU1128801A (en) | Agents for treating human diseases, especially for treating tumors such as colonic cancers and melanomas or for regenerating tissue and promoting hair growth | |
| AU2821000A (en) | Matrix protein compositions for induction of apoptosis | |
| AU1991901A (en) | Pharmaceutical composition for treating and preventing human tumors, which express the tumor antigen mucin and/or the carcinoembryonic antigen (cea), and the use thereof | |
| WO1998007415A3 (en) | Methods for prevention of cellular proliferation and restenosis | |
| WO2001036048A8 (en) | Phorboxazole derivatives for treating cancer | |
| IL164356A0 (en) | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy | |
| AU5939898A (en) | Agent for the pre-symptomatic detection, prevention and treatment of breast cancer in humans | |
| FI964672A0 (fi) | Viljankäsittelymenetelmä, käsitelty vilja ja sen käyttö | |
| ZA979655B (en) | Conjugates useful in the treatment of prostate cancer. | |
| UA34368A (uk) | Спосіб лікування рака молочної залози |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |